amsacrine has been researched along with Abnormalities, Autosome in 22 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to determine and compare the clastogenicity of m-AMSA and camptothecin (CAMP) in vivo in mouse bone marrow and peripheral blood lymphocytes (PBLs), and in vitro in mouse lymphoma L5178Y cells." | 3.68 | Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. ( Allen, JW; Backer, LC; Campbell, JA; DeMarini, DM; Doerr, CL; Harrington-Brock, K; Howard, DR; Kligerman, AD; Moore, MM, 1990) |
| "We propose two mechanisms for aneuploidy by amsacrine (or related topo II poisons), either of which can be readily detected using FISH." | 1.29 | Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine. ( Baguley, BC; Ferguson, LR; Holdaway, KM; Whiteside, G, 1996) |
| "The frequencies of chromosomal aberrations and sister chromatid exchanges (SCE) were studied in human peripheral lymphocytes after exposure of whole blood cultures to the antitumour agent m-AMSA." | 1.28 | The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA. ( Andersson, HC; Kihlman, BA, 1989) |
| "The antitumor drug amsacrine causes chromosomal aberrations both in cultured cells (L1210 murine leukemia and HeLa cells) and in vivo (L1210 leukemia)." | 1.27 | Relationship between the induction of chromosome damage and cytotoxicity for amsacrine and congeners. ( Baguley, BC; Ferguson, LR, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (40.91) | 18.7374 |
| 1990's | 10 (45.45) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perel, Y | 1 |
| Auvrignon, A | 1 |
| Leblanc, T | 1 |
| Michel, G | 1 |
| Vannier, JP | 1 |
| Dalle, JH | 1 |
| Gandemer, V | 1 |
| Schmitt, C | 1 |
| Mèchinaud, F | 1 |
| Lamagnere, JP | 1 |
| Piguet, Ch | 1 |
| Couillaud, G | 1 |
| Pautard, B | 1 |
| Baruchel, A | 1 |
| Leverger, G | 1 |
| Parry, JM | 1 |
| Fowler, P | 1 |
| Quick, E | 1 |
| Parry, EM | 1 |
| Ferguson, LR | 5 |
| Baguley, BC | 3 |
| Wilson, WR | 1 |
| Harris, NM | 1 |
| Allen, JW | 2 |
| Poorman-Allen, P | 1 |
| Collins, BW | 1 |
| Sontag, MR | 1 |
| Thomas, X | 1 |
| Archimbaud, E | 1 |
| Charrin, C | 1 |
| Magaud, JP | 1 |
| Fiere, D | 1 |
| Cortés, F | 3 |
| Piñero, J | 3 |
| Palitti, F | 2 |
| Whiteside, G | 1 |
| Holdaway, KM | 1 |
| Mosesso, P | 1 |
| Darroudi, F | 1 |
| van den Berg, M | 1 |
| Vermeulen, S | 1 |
| Natarajan, AT | 1 |
| López-Baena, M | 1 |
| Mateos, S | 1 |
| Sumner, AT | 2 |
| Nørgaard, JM | 1 |
| Olesen, LH | 1 |
| Olesen, G | 1 |
| Meyer, K | 1 |
| Kristensen, JS | 1 |
| Bendix, K | 1 |
| Pedersen, B | 1 |
| Kjeldsen, E | 1 |
| Hokland, P | 1 |
| Backer, LC | 1 |
| Harrington-Brock, K | 2 |
| Campbell, JA | 1 |
| DeMarini, DM | 2 |
| Doerr, CL | 3 |
| Howard, DR | 1 |
| Kligerman, AD | 1 |
| Moore, MM | 3 |
| Andersson, HC | 1 |
| Kihlman, BA | 1 |
| Pommier, Y | 2 |
| Kerrigan, D | 1 |
| Covey, JM | 1 |
| Kao-Shan, CS | 2 |
| Whang-Peng, J | 2 |
| Meyer, MK | 1 |
| Brock, KH | 1 |
| Hozier, J | 1 |
| Zwelling, LA | 1 |
| Bradley, MO | 1 |
| van Zijl, P | 2 |
| Nesnow, S | 1 |
1 trial available for amsacrine and Abnormalities, Autosome
| Article | Year |
|---|---|
Maintenance therapy in childhood acute myeloid leukemia.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow | 2004 |
21 other studies available for amsacrine and Abnormalities, Autosome
| Article | Year |
|---|---|
Investigations into the biological relevance of in vitro clastogenic and aneugenic activity.
Topics: Alkylating Agents; Amsacrine; Aneuploidy; Cells, Cultured; Chromosome Aberrations; Chromosomes, Huma | 2004 |
Relationship between the induction of chromosome damage and cytotoxicity for amsacrine and congeners.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Chromosome Aber | 1984 |
Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells.
Topics: Aminoacridines; Amsacrine; Animals; Carcinogens; Cell Division; Cell Line; Cell Survival; Chromosome | 1984 |
Synaptonemal complex aberrations in the pseudoautosomal region of X, Y chromosomes in irradiated hamsters.
Topics: Amsacrine; Animals; Bleomycin; Chromosome Aberrations; Cricetinae; Cricetulus; DNA Damage; Male; Mic | 1994 |
CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Aneuploidy; Antibiotics, Antineoplastic; Antigens, CD; Antigens, | 1995 |
Cytogenetic effects of inhibition of topoisomerase I or II activities in the CHO mutant EM9 and its parental line AA8.
Topics: Amsacrine; Animals; Camptothecin; CHO Cells; Chromosome Aberrations; Cricetinae; DNA Topoisomerases, | 1993 |
Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Death; CHO Cells; Chromosome Aberrations; Cricetinae; DNA Dam | 1994 |
Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
Topics: Amsacrine; Analysis of Variance; Aneuploidy; Animals; Antineoplastic Agents; Cell Cycle; Cell Divisi | 1996 |
Induction of chromosomal aberrations (unstable and stable) by inhibitors of topoisomerase II, m-AMSA and VP16, using conventional Giemsa staining and chromosome painting techniques.
Topics: Amsacrine; Azure Stains; Chromosome Aberrations; Chromosome Banding; Etoposide; Humans; Male; Staini | 1998 |
Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine.
Topics: Amsacrine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, P | 1998 |
Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II.
Topics: Amsacrine; Animals; CHO Cells; Chromatids; Chromosome Aberrations; Chromosome Segregation; Cricetina | 1998 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplas | 2001 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerase | 1992 |
Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro.
Topics: Amsacrine; Animals; Bone Marrow; Bone Marrow Cells; Camptothecin; Cell Line; Chromatids; Chromosome | 1990 |
Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoacridines; Amsacrine; Animals; Bleomycin; Chromosome Aberrati | 1989 |
The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA.
Topics: Amsacrine; Cell Cycle; Cells, Cultured; Chromosome Aberrations; Chromosomes; Culture Media; Cytarabi | 1989 |
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Line; Cell Survival; Chromosome Aberrations; Cricetinae; Drug | 1988 |
Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase.
Topics: Amsacrine; Animals; Cell Survival; Chromosome Aberrations; DNA Topoisomerases, Type II; Hypoxanthine | 1987 |
Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells.
Topics: Aminoacridines; Amsacrine; Animals; Cell Survival; Cells, Cultured; Chromosome Aberrations; Cricetin | 1985 |
Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921.
Topics: Amsacrine; Animals; Cell Line; Cell Nucleus; Cell Transformation, Neoplastic; Chromosome Aberrations | 1988 |
Morphological transformation and chromosome damage by amsacrine in C3H/10T1/2 clone 8 cells.
Topics: Aminoacridines; Amsacrine; Animals; Cell Line; Cell Nucleus; Cell Survival; Cell Transformation, Neo | 1986 |